NXGL Share Price Performance
US$0.58
-2.03 (-77.74%)
86.5% undervalued intrinsic discount
US$4.30
Fair Value
Price US$0.58
JohnDoe4mFuture US$4.30
AnalystConsensusTarget US$6.00
Fair ValueUS$4.30
Share Pricen/a
NEXGEL, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 10 Fair Values set on narratives written by author
NXGL Community Narratives
JO
Fair Value
·Fair Value US$4.3 86.5% undervalued intrinsic discount
NexGel (NXGL): The $5M Market Cap Trading at a $35M Revenue Reality
1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$6 90.3% undervalued intrinsic discount
Hydrogel Adoption And Gentle Skincare Demand Will Drive Strong Long Term Upside
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
NexGel (NXGL): The $5M Market Cap Trading at a $35M Revenue Reality
The Hook: A Massive Valuation Disconnect While the market has pinned NexGel (NXGL) to its 52-week lows near $0.58 , the underlying business has just undergone a fundamental "rebirth." According to Simply Wall St’s intrinsic value model, the stock is currently 86.5% undervalued , with a fair value estimate of $4.30. This creates a rare setup where the market cap ($5M) is significantly lower than the company's projected annual revenue.Read more
JO
US$4.3
86.5% undervalued intrinsic discount
Fair Value
Profit Margin
13.43%
Future PE
25.01x
Price in 2031
US$6.68
Hydrogel Adoption And Gentle Skincare Demand Will Drive Strong Long Term Upside
Catalysts About NEXGEL NEXGEL develops and manufactures advanced hydrogel based wound care, medical device and consumer beauty products for global partners and its own brands. What are the underlying business or industry changes driving this perspective?Read more
AN
US$6
90.3% undervalued intrinsic discount
Fair Value
Profit Margin
0.12%
Future PE
20.07x
Price in 2028
US$0.08
Trending Discussion
Recently Updated Narratives
JO
NexGel (NXGL): The $5M Market Cap Trading at a $35M Revenue Reality
Fair Value: US$4.3 86.5% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Hydrogel Adoption And Gentle Skincare Demand Will Drive Strong Long Term Upside
Fair Value: US$6 90.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
NEXGEL, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.35
- 39.48%
- -26.27%
- 12.0%
About NXGL
- Founded
- 2009
- Employees
- 19
- CEO
- WebsiteView website
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Lumagel Beauty, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
